Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601013 | 0.88 | IKBKB (0.77) | IKBKBCHUK | |
| SCHEMBL4602290 | 0.87 | IKBKB (0.63) | IKBKB | |
| SCHEMBL4600607 | 0.87 | IKBKB (0.76) | IKBKB | |
| Hydrochloric Acid SCHEMBL4946386 | 0.87 | IKBKB (0.76) | IKBKBCHUK | |
| SCHEMBL4600523 | 0.87 | IKBKB (1.00) | IKBKBCHUK | |
| SCHEMBL14028521 | 0.87 | IKBKB (0.74) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4944389 | 0.86 | IKBKB (0.98) | IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL4939095 | 0.86 | IKBKB (0.73) | IKBKBCHUK | |
| SCHEMBL14046398 | 0.86 | IKBKB (0.73) | IKBKBCHUK | |
| SCHEMBL14046495 | 0.84 | IKBKB (0.70) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912646-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | Bayer HealthCare AG (DE) | 2008-04-23 | — | — | EP | claimed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2007014671-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-02-08 | — | — | WO | claimed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | claimed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| EP-1912646-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | Bayer HealthCare AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| WO-2007014671-A2 | COMBINATIONS CONTAINING IKK-BETA INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-02-08 | — | — | WO | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | disclosed |
| EP-1326856-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | Bayer Aktiengesellschaft (DE) | 2003-07-16 | — | — | EP | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| WO-2002024679-A1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-β) INHIBITING ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | IKBKB 1024/4885CHUK 372/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | IKBKB 2996/4885CHUK 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.